BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CHS Pharma Acquires Intellectual Property Portfolio


2/13/2013 12:06:08 PM

Jupiter, Florida February 12, 2013. CHS Pharma Inc. an emerging pharmaceutical company has acquired the Intellectual Property Portfolio for the Treatment and Prevention of Cancer and Prevention of Age Related Diseases from Florida Atlantic University Research Corporation located in Boca Raton, Florida and the Hospital for Special Surgery affiliated with the Weill Cornell Medical College located in New York City, New York. The acquired Intellectual Property is based on the research by Distinguished Research Professor Dr. Herbert Weissbach, former Roche Executive, member of the National Academy of Sciences, and the Director of the Center for Molecular Biology and Biotechnology at FAU’s Jupiter campus. According to the studies conducted by Dr. Weissbach and his research team, cancer cells are selectively targeted and killed while normal healthy cells are protected. The age related studies have shown that by preconditioning cells, heart attack, stroke, and diseases such as Dry Macular Degeneration, a retina disease leading to blindness, can be mitigated.

CHS Pharma co-Founder and Chief Executive Officer, Stephen Chakoff stated that this milestone will significantly increase the value of our company and position us to enter into strategic partnerships leading to New Drug Approvals. CHS Pharma’s first focus is a topical gel treatment for a precancerous skin condition known as Actinic Keratosis (AK). Actinic Keratosis is a major healthcare problem affecting the growing “baby boomer” population. If left untreated 65% of AK results in Squamous Cell Carcinomas, and 36% will result in Basal Cell Carcinomas.

For further information contact.

Saeid Rezvankhah, Chief Operating Officer

sr@chspharma.com

561 748 9393 telephone

www.chspharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES